This case represents the first to our knowledge to discuss re-treatment with pembrolizumab for relapsed choriocarcinoma after achieving a complete response.
No takes yet. Share an insight, caveat, or question.
Wong et al. (2022) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: